Unfortunately, currently-available PTH1R agonists have systemic side effects that preclude their use for bladder diseases, and bladder-specific derivatives are awaited to allow the clinical translation of the PTHrP-PTH1R axis for treating bladder diseases. Here, PTH1R is linked to urinary bladder disorder.